Experts at the American Academy of Dermatology Annual Meeting shared results of research into various topical and systemic therapies for atopic dermatitis (AD) and hidradenitis suppurativa during a late-breaking abstract session.
Approved in 2022 for psoriasis, the manufacturer has submitted an application for approval of tapinarof cream for treating atopic dermatitis in adults and children 2 years of age and older.